ATE243526T1 - Chemokin bindendes protein und verfahren zu seiner verwendung - Google Patents

Chemokin bindendes protein und verfahren zu seiner verwendung

Info

Publication number
ATE243526T1
ATE243526T1 AT96921023T AT96921023T ATE243526T1 AT E243526 T1 ATE243526 T1 AT E243526T1 AT 96921023 T AT96921023 T AT 96921023T AT 96921023 T AT96921023 T AT 96921023T AT E243526 T1 ATE243526 T1 AT E243526T1
Authority
AT
Austria
Prior art keywords
binding protein
chemokine binding
poxviruses
interferon
chronic
Prior art date
Application number
AT96921023T
Other languages
English (en)
Inventor
Grant Mcfadden
Alexandra Lucas
Original Assignee
Robarts John P Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts John P Res Inst filed Critical Robarts John P Res Inst
Application granted granted Critical
Publication of ATE243526T1 publication Critical patent/ATE243526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96921023T 1995-04-19 1996-04-19 Chemokin bindendes protein und verfahren zu seiner verwendung ATE243526T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42485095A 1995-04-19 1995-04-19
PCT/IB1996/000680 WO1996033730A2 (en) 1995-04-19 1996-04-19 Chemokine binding protein and methods of use therefor

Publications (1)

Publication Number Publication Date
ATE243526T1 true ATE243526T1 (de) 2003-07-15

Family

ID=23684134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921023T ATE243526T1 (de) 1995-04-19 1996-04-19 Chemokin bindendes protein und verfahren zu seiner verwendung

Country Status (11)

Country Link
US (1) US5834419A (de)
EP (1) EP0840615B1 (de)
JP (2) JP4077876B2 (de)
AT (1) ATE243526T1 (de)
AU (1) AU718049B2 (de)
CA (1) CA2218499C (de)
DE (1) DE69628838T2 (de)
DK (1) DK0840615T3 (de)
ES (1) ES2202452T3 (de)
PT (1) PT840615E (de)
WO (1) WO1996033730A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495515B1 (en) * 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
EP1034789A1 (de) * 1996-05-22 2000-09-13 University Of Alberta Typ-2 Chemokine-Bindende Proteine und Verfahren zu deren Verwendung
WO1997044054A2 (en) * 1996-05-22 1997-11-27 University Of Alberta Type-2 chemokine binding proteins and methods of use therefor
EP0985046B1 (de) 1997-02-21 2006-04-12 Oxxon Therapeutics Limited Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
WO1999034818A1 (en) * 1998-01-09 1999-07-15 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Broad spectrum chemokine antagonist and uses thereof
US6869606B1 (en) 1999-02-22 2005-03-22 Millennium Pharmaceuticals, Inc. Biotinylated-chemokine antibody complexes
US6589933B1 (en) 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
EP1200595A2 (de) * 1999-07-12 2002-05-02 Viron Therapeutics, Inc. Gene vom myxomavirus, die für die immunmodulation benutzt werden können
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
DK1339737T3 (da) 2000-12-04 2007-10-15 Viron Therapeutics Inc Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
WO2002080948A1 (en) * 2001-04-05 2002-10-17 The Trustees Of Princeton University Compositions and methods for treating inflammation and related conditions
WO2002090381A1 (en) * 2001-05-04 2002-11-14 Surromed Inc. Chemokine-binding proteins for treating congestive heart failure
US20030083305A1 (en) * 2001-10-10 2003-05-01 Peter Palese Viral interferon antagonists and uses therefor
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US20030161937A1 (en) * 2002-02-25 2003-08-28 Leiby Mark W. Process for coating three-dimensional substrates with thin organic films and products
WO2003092615A2 (en) * 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
EP1572736A2 (de) * 2002-12-10 2005-09-14 Endocube SAS Thap proteine als nukleare rezeptoren für chemokine und ihre rolle in der transkriptionsregulation, der zellproliferierung und der zelldifferenzierung
JP2007020401A (ja) * 2003-10-23 2007-02-01 Univ Kurume 可溶型インターフェロンγ受容体遺伝子導入法
WO2006074179A2 (en) * 2005-01-04 2006-07-13 University Of Rochester Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease
MX2010001307A (es) * 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer
US20140130375A1 (en) 2012-11-15 2014-05-15 Nike, Inc. Article Of Footwear Incorporating A Knitted Component

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
CA2081309A1 (en) * 1990-04-24 1991-10-25 Paul J. Zavodny Soluble, truncated gamma-interferon receptors

Also Published As

Publication number Publication date
DK0840615T3 (da) 2003-08-18
CA2218499A1 (en) 1996-10-31
PT840615E (pt) 2003-10-31
EP0840615A2 (de) 1998-05-13
JPH11504036A (ja) 1999-04-06
ES2202452T3 (es) 2004-04-01
AU718049B2 (en) 2000-04-06
EP0840615B1 (de) 2003-06-25
WO1996033730A2 (en) 1996-10-31
US5834419A (en) 1998-11-10
AU6237996A (en) 1996-11-18
JP2007332145A (ja) 2007-12-27
DE69628838D1 (de) 2003-07-31
DE69628838T2 (de) 2004-05-06
JP4077876B2 (ja) 2008-04-23
CA2218499C (en) 2007-02-20
WO1996033730A3 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
DE69628838D1 (de) Chemokin bindendes protein und verfahren zu seiner verwendung
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
BR9808646A (pt) Sequenciador de gene e processos
DE69703040D1 (de) Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung
FI942660A7 (fi) Actinoplanes sp:stä olevia lipopeptidejä, joilla on farmakologista vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
FR2706484B1 (fr) Polypeptide mutant de la protéine kinase C, séquences d'acides nucléiques codant pour ledit polypeptide et leurs utilisations.
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
AUPP627498A0 (en) Novel peptides - i
DE69821053D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidyl-Gruppen enthaltenden Polytriazinen
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
EE200000356A (et) DNA molekul, mis kodeerib mutantset prepro-neuropeptiidi Y, mutantne signaalpeptiid ja nende kasutamine
PE20399A1 (es) Muteina ob
DK210088A (da) Fremgangsmaade til selektiv spaltning af peptidbindinger, isaer med henblik paa bestemmelse af aminosyresekvenser
DE59611293D1 (de) Protein mit dnase-aktivität
ATE307201T1 (de) Srcr domäne-enthaltendes protein
EP0588036A3 (de) Zusammensetzung zur Isolierung von Apaminrezeptoren, Apaminbindungsprotein und deren Verwendungen.
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein
DE69831888D1 (de) Nicht pathogener mutanter E. coli Stamm, Verfahren zur dessen Herstellung und Verwendung
FI956041A7 (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalis ia vasta-aineita CD44V6 vastaan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0840615

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee